Drugs / PF-04605412
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00915278 | Sep 2009 → Jan 2013 | cancer of unknown primary site | Pfizer | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-04605412 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00915278 ↗ |
| Action | Inhibit | “Fibronectin receptor alpha inhibitor” CHEMBL2109622 ↗ |
| Modality | Monoclonal antibody | “A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412” NCT00915278 ↗ |
| Route | Intravenous | “PF-04605412 will be administered as 2 hr IV infusion” NCT00915278 ↗ |
| Target | ITGA5 | “Fibronectin receptor alpha inhibitor” CHEMBL2109622 ↗ |